United Therapeutics UTHR Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total revenues by Product | |||||
| Adcirca | $30M+26.1% | $23.8M-17.6% | $28.9M-30.0% | $41.3M-26.1% | |
| Nebulized Tyvaso | $585.7M-0.2% | $586.8M+16.8% | $502.6M— | —— | |
| Orenitram | $496.9M+14.4% | $434.3M+20.8% | $359.4M+10.6% | $325.1M+6.2% | |
| Remodulin | $526.8M-2.1% | $538.1M+8.8% | $494.8M-1.1% | $500.2M-2.6% | |
| Tyvaso DPI | $1.29B+25.0% | $1.03B+41.4% | $731.1M— | —— | |
| Unituxin | $226.8M-5.0% | $238.7M+20.0% | $198.9M+8.7% | $182.9M-9.6% | |
| Gross Profit by Product | |||||
| Adcirca | $16.9M+23.4% | $13.7M-17.5% | $16.6M-29.4% | $23.5M-26.6% | |
| Nebulized Tyvaso | $558.5M+1.0% | $552.7M+17.5% | $470.2M— | —— | |
| Orenitram | $468.2M+15.3% | $405.9M+21.1% | $335.2M+10.7% | $302.7M+5.7% | |
| Remodulin | $477.5M-2.7% | $490.7M+7.5% | $456.6M-2.1% | $466.2M-2.0% | |
| Tyvaso DPI | $1.08B+22.2% | $885.2M+43.8% | $615.5M— | —— | |
| Unituxin | $209.3M-6.7% | $224.3M+23.0% | $182.4M+7.4% | $169.8M-9.7% | |
| Royalty as a percentage of net sales by Product | |||||
| Adcirca | 10%0.0pp | 10%0.0pp | 10%— | —— | |
| Tyvaso DPI | 10%0.0pp | 10%0.0pp | 10%— | —— | |
| Unituxin | 1%0.0pp | 1%0.0pp | 1%0.0pp | 1%0.0pp | |
| Cost of Sales by Product | |||||
| Adcirca | $13.1M+29.7% | $10.1M-17.9% | $12.3M-30.9% | $17.8M-25.5% | |
| Nebulized Tyvaso | $27.2M-20.2% | $34.1M+5.2% | $32.4M— | —— | |
| Orenitram | $28.7M+1.1% | $28.4M+17.4% | $24.2M+8.0% | $22.4M+13.7% | |
| Remodulin | $49.3M+4.0% | $47.4M+24.1% | $38.2M+12.4% | $34M-10.3% | |
| Tyvaso DPI | $210.6M+41.9% | $148.4M+28.4% | $115.6M— | —— | |
| Unituxin | $17.5M+21.5% | $14.4M-12.7% | $16.5M+26.0% | $13.1M-7.7% | |
| Total revenues by Geography | |||||
| ROW | $145.7M+5.8% | $137.7M+9.9% | $125.3M+2.5% | $122.2M+0.7% | |
| U.S. | $3.04B+10.9% | $2.74B+24.4% | $2.2B+21.4% | $1.81B+16.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does United Therapeutics break its business down?
- United Therapeutics (UTHR) reports total revenues by product across 6 parts — Adcirca, Nebulized Tyvaso, Orenitram, Remodulin and Tyvaso DPI. Each is extracted from the segment footnotes and tracked over time.
- Where does United Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in United Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
